Recent news on Hepsera

Pharma Sector: Few Newsmakers Of The Week - Idenix, Nabi, CSL ...  -  May 5, 2007
Trading Markets,Gilead Sciences' Hepsera and GlaxoSmithKline's Zeffix are the two main competitors to Tyzeka in the marketplace. Maxim Group analysts estimate the peak

Gilead Sciences maakt eerstekwartaalcijfers 2007 bekend  -  Apr 19, 2007
Netherlands Corporate News (persbericht),Hepsera for Chronic Hepatitis B Hepsera sales totaled $71.3 million for the first quarter of 2007, a 35 percent increase from $52.7 million in the first

Gilead Sciences Announces First Quarter 2007 Financial Results  -  Apr 18, 2007
Genetic Engineering News (press release),Hepsera sales totaled $71.3 million for the first quarter of 2007, a 35 percent increase from $52.7 million in the first quarter of 2006.

Gilead Q1 Profit Soars 55% On Strong HIV Drug Sales  -  Apr 18, 2007
Trading Markets,The company's non HIV products, which include Hepsera and AmBisome also fared well in the just concluded first quarter. Sales of Hepsera, which is

Gilead Sciences Reports Quarterly Earnings Growth of 55%  -  Apr 18, 2007
CNBC,Hepsera sales rose 35% to $71.3 million, while Ambisome sales rose 14% to $61.5 million. Foster City, California,-based Gilead also collects royalties on

Gilead First Quarter Profit Rises 55 Percent  -  Apr 18, 2007
Reuters.uk,...the guidance," he said, noting first-quarter sales of anti-fungal drug Ambisome and hepatitis drug Hepsera were stronger than the company had expected.

AIDS drug maker for the world producing around the clock at city plant  -  Apr 13, 2007
Edmonton Journal (subscription),The plant also produces Hepsera, a hepatitis B treatment sold in 30 countries. Viread came along in 2001, Hepsera a year later followed by Emtriva,

Gilead's Atripla, Lower Costs Provide Lift To First Quarter  -  Apr 22, 2007
BioWorld Online,..."I had very aggressive estimates for Atripla, and [Gilead] didn't quite make them," Seiler told BioWorld Today, but AmBisome and Hepsera (for non-HIV

Gilead Sciences Announces First Quarter 2007 Financial Results  -  Apr 18, 2007
Business Wire (press release),Hepsera ® (adefovir dipivoxil) and AmBisome ® (amphotericin B) liposome for injection also experienced solid sales growth compared to the same quarter last

Analysis: Gilead's future looks bright  -  Apr 19, 2007
United Press InternationalSales of Gilead's hepatitis B treatment Hepsera rose 35 percent to $71.3 million. "We are very pleased with the solid results, including revenues of over $1

Gilead Sciences profit surges 55%  -  Apr 18, 2007
MarketWatchFirst-quarter sales of the company's chronic hepatitis B treatment Hepsera outpaced expectations at $71.3 million. That compared with a $64.3 million

Gilead quarterly profit, revenue seen up 43%  -  Apr 17, 2007
MarketWatchFirst-quarter sales of the company's chronic hepatitis B treatment Hepsera are expected to total $64.3 million vs. $65.9 million, while fungal infection

Fresh from the Pipeline: Telbivudine  -  Apr 5, 2007
Nature.com (subscription),It has since been joined on the market by the nucleotide analogue adefovir dipivoxil (Hepsera; Gilead) and the nucleoside analogues entecavir (Baraclude;

Gilead Sciences: Rapid Growth Expected From New Products  -  Apr 3, 2007
Seeking Alpha,...of Truvada (emtricitabine and tenofovir disoproxil fumarate) and Viread (tenofovir disoproxil fumarate), as well as Hepsera (adefovir dipivoxil).

Metabasis Therapeutics Reports on 2006 Financial Results and ...  -  27 Mar 2007
Drug Newswire (press release),In fact, the 30 mg dose of pradefovir resulted in about twice as many patients achieving undetectable levels of HBV DNA as seen with 10 mg Hepsera (71% of

Refusal to pay for drug sparks outrage in BC  -  Mar 21, 2007
Globe and Mail,Many hepatitis sufferers build up a drug resistance, but those patients are able to control their symptoms with Hepsera, he said.

BC likened to US after refusal to pay for costly treatment  -  Mar 22, 2007
Globe and Mail,About 350 BC residents are currently receiving Adefovir dipivoxil, marketed as Hepsera, for free, but those giveaways will come to an end by July.

Czech scientists claim US drugmaker shelving powerful new drug  -  Mar 7, 2007
Monsters and Critics.com,US drugmaker Gilead Sciences markets as Viread and Hepsera, the new substance named MK 612 is much more effective and less toxic than its predecessors.

Cramer is right on with Gilead Sciences  -  Mar 1, 2007
Blogging StocksGILD also owns the major part of the Hepatitis B market with Hepsera. Gilead is the maker of Tamiflu which treats influenza. Tamiflu is being stock piled by

Anti-HBV drug entecavir also active against HIV and promotes ...  -  Mar 1, 2007
Aidsmap,Two agents currently approved for the treatment of hepatitis B virus (HBV) infection – lamivudine (3TC; Epivir-HBV) and adefovir (Hepsera) also demonstrate

Gilead Sciences meldt financiële resultaten kw4 en jaar 2006  -  Jan 31, 2007
Netherlands Corporate News (persbericht),Hepsera for Chronic Hepatitis B Hepsera sales were $65.9 million for the fourth quarter of 2006, a 29 percent increase from $51.2 million for the fourth

- Fourth Quarter Net Loss Per Share of $(3.62); Fourth Quarter Non ...  -  Feb 1, 2007
boerse.de (Pressemitteilung),Hepsera sales were $65.9 million for the fourth quarter of 2006, a 29 percent increase from $51.2 million for the fourth quarter of 2005.

Thursday's Analysts' Upgrades and Downgrades  -  Feb 1, 2007
TheStreet.comGrowth driven by strong HIV sales, Hepsera upside, royalty upside and solid margins. Maintained Buy rating. Harte-Hanks (HHS - Cramer's Take - Stockpickr)

Gilead Sciences Posts Q4 Loss On Charges; EPS Beats View; Stock Up ...  -  Jan 31, 2007
Trading Markets,Hepsera sold for $65.9 million, up 29%, in the latest quarter. Selling, general and administrative expenses for the fourth quarter of 2006 were $147.1

Hana Biosciences Announces Vice President Appointments in Clinical ...  -  Jan 5, 2007
PharmaLive.com (press release),Inc. where he was involved in the clinical development of Viread(r) for the treatment of HIV, and Hepsera(r) for the treatment of hepatitis B infection.

Idenix Pharmaceuticals initiated with "buy"  -  Dec 6, 2006
newratings.com...market opportunity and capture market share from two competing and widely prescribed drugs, Glaxo’s Epivir HBV and Gilead’s Hepsera, the analysts say.

Gilead Q3 2006 Earnings Call Transcript  Oct 18, 2006
Hepsera for the treatment of chronic hepatitis B had sales of $55 million in the third quarter of 2006, an 18% increase compared to the third quarter of 2005 ... -Seeking Alpha, Bristol's Baraclude beats rival in tiny trial  Oct 30, 2006
...on Monday said its drug Baraclude was more effective in a small trial than Gilead Science Inc's (GILD.O: Quote, Profile, Research) drug Hepsera in knocking ... -Reuters Gilead Sciences meldt derde kwartaalresultaten 2006  Oct 18, 2006
200 mg/ tenofovir disoproxil fumarate 300 mg) following its US launch in July of this year, as well as continued solid product sales of Hepsera(R) (adefovir ... -Netherlands Corporate News (persbericht), Pharma Sector - Few Newsmakers Of The Week: Tercica, Adherex ...  Nov 4, 2006
...receiving its oral antiviral therapy Baraclude demonstrated greater viral load reduction of hepatitis B than patients treated with Gilead Science's Hepsera. ... -Trading Markets, Gilead posts Q3 loss of $52.2M on buyout costs  Oct 18, 2006
...said growth continues to be driven primarily by its HIV product franchise, including Truvada and Atripla, as well as continued solid product sales of Hepsera. ... -San Jose Business Journal, Gilead Sciences Announces Third Quarter 2006 Financial Results  Oct 18, 2006
...tenofovir disoproxil fumarate 300 mg) following its US launch in July of this year, as well as continued solid product sales of Hepsera ® (adefovir dipivoxil ... -Business Wire (press release), Pharma Sector: Few Newsmakers Of The Week - Novartis, Abbott ...  Oct 28, 2006
Other approved monotherapies for HBV are GlaxoSmithKline's Epivir-HB (lamivudine), Gilead Sciences' Hepsera (adefovir), Bristol-Myers Squibb's Baraclude ... -Trading Markets, Liver transplants can be successful in HIV patients with hepatitis ...  Sep 5, 2006
Patients taking Tenofovir ( Viread ) and/or Adefovir ( Hepsera ) were more likely to survive with or without a transplant, indicating that controlling HBV is ... -Xagena.it

Idenix Pharmaceuticals initiated with "buy"  -  Dec 6, 2006
newratings.com...market opportunity and capture market share from two competing and widely prescribed drugs, Glaxo’s Epivir HBV and Gilead’s Hepsera, the analysts say.

Clinicians Expect Bristol-Myers Squibb's Baraclude Use to Increase ...  Aug 2, 2006
However, Baraclude and Gilead's Hepsera Face Hurdles in Achieving Favorable Tier Status Amongst Surveyed Private Health Plans, According to a New Report from ... -PR Newswire

Clinicians Expect Bristol-Myers Squibb's Baraclude Use to Increase ...  Aug 2, 2006
Hepatitis B: New Antivirals Replacing the Old?, also finds that while clinician use of Baraclude will increase, Baraclude and Gilead's Hepsera are facing ... -PR Newswire

Idenix Shares Fall on Downgrade  Aug 18, 2006
Also, the US market for hepatitis treatments is relatively small with strong competition, Ho wrote, pointing to Gilead Sciences Inc.'s Hepsera and Bristol ... -MSN Money

Czechs' R&D role in bird flu, HIV  Aug 7, 2006
The Czech contribution includes Vistide [an antiviral medication], Hepsera [a Hepatitis B treatment] and Viread [HIV treatment]. ... -Czech Business Weekly

Gilead Sciences, Inc. Q2 2006 Earnings Conference Call Transcript ...  Jul 20, 2006
Hepsera for the treatment of chronic hepatitis B had sales of $57 million dollars in the second quarter of 2006, a 24% increase compared to the second quarter ... -Seeking Alpha

AIDS drug researcher Holy receives grant  Jul 13, 2006
Another efficient substance developed with Holy´s assistance and used by Gilead, is adefovir, that was approved in 2002 as the drug Hepsera, designed to treat ... -Prague Daily Monitor

Zoek in het archief  Jul 13, 2006
...for the treatment of CMV retinitis in AIDS patients, Viread(R) (tenofovir disoproxil fumarate) for the treatment of HIV infection and Hepsera(R) (adefovir ... -Netherlands Corporate News (persbericht)

Gilead Sciences and the IOCB Establish Academic Research Centre in ...  Jul 14, 2006
...the treatment of CMV retinitis in AIDS patients, Viread ® (tenofovir disoproxil fumarate) for the treatment of HIV infection and Hepsera ® (adefovir dipivoxil ... -CombiChem.net (subscription)

Hepatitis B drug gets European approval  Jun 28, 2006
...(GILD.O: Quote, Profile, Research) called Hepsera. All four drugs are nucleoside analogues, which disrupt the enzyme that reproduces the hepatitis B virus. ... -Reuters

EU approval of BMS’ HBV drug gives alternative treatment option  Jul 5, 2006
...its drug is significantly successful on patient management of the virus than GlaxoSmithKline's lamivudine, Novartis' telbivudine, or Gilead Sciences' Hepsera. ... -DrugResearcher.com



Funding widened for hepatitis  Apr 5, 2006
Wayne McNee said today that from May 1, access would be widened for lamivudine (Zeffix) and a new type of hepatitis therapy adefovir (Hepsera) would be funded. ... - Stuff.co.nz

Good news for Hep B sufferers  Apr 5, 2006
He says adefovir, sold under the name Hepsera, is used when the former drug fails. It was only approved by Medsafe in August 2005. ... - NZ City

Funding moves take on hepatitis B  Apr 5, 2006
From 1 May 2006 access will be widened to lamivudine (Zeffix), and a new type of hepatitis therapy, adefovir (Hepsera) will be funded. ... - Scoop.co.nz

Metabasis Therapeutics Says Phase 2 Study Shows Pradefovir Reduces ...  Mar 16, 2006
2 study of pradefovir, an oral anti-viral product candidate to treat hepatitis B, after 48 weeks showed greater reduction in viral load compared to Hepsera. ... - Trading Markets

Metabasis Comments on Positive 48 Week HBV Data From Pradefovir ...  Mar 16, 2006
10) drop in hepatitis B viral (HBV) DNA, a measure of viral load, from baseline as compared to a 4.19 log(10) drop in the 10 mg (QD) Hepsera (adefovir dipivoxil ... - PR Newswire

Valeant Says Phase 2 Study Of Pradefovir Shows Statistically ...  Mar 16, 2006
...reported the Phase 2 study results of its oral anti-viral compound, pradefovir, which showed statistically superior viral load reduction compared to Hepsera. ... - Trading Markets

Valeant Pharmaceuticals Reports Positive Data from Pradefovir ...  Mar 16, 2006
The Phase 2 study consisted of five treatment groups: pradefovir - 5, 10, 20 and 30 mg/day (QD), and Hepsera (adefovir dipivoxil) - 10 mg/day (QD), with an ... - Genetic Engineering News

Metabasis Therapeutics Reveals Results From Phase 2 Study Of ...  Mar 16, 2006
Hepsera, a non-liver targeted pro-drug of adefovir, was approved by the Food and Drug Administration for use at 10 mg, however, previous clinical trials showed ... - Trading Markets

Valeant Reveals Results Of Phase 2 Study Of Pradefovir - Quick ...  Mar 16, 2006
The company said that in the Phase 2 study, 10, 20 and 30 mg of pradefovir had a statistically superior viral load reduction compared to 10 mg of Hepsera. - Trading Markets

Valeant hepatitis B drug beats rival in trial  Mar 20, 2006
Results so far show that 10, 20 and 30mg of pradefovir had a statistically superior viral load reduction compared to 10mg dosages of Gilead Sciences' Hepsera. ... - Pharmaceutical Business Review

Baraclude Beats Epivir for Hepatitis B  Mar 8, 2006
Not included in the contest is a third antiviral drug, Hepsera. ... Epivir, Hepsera, and Baraclude do prevent progression of hepatitis B disease. ... - WebMD

Health council urges NIS 466m. expansion of services  Mar 29, 2006
...adjuvant treatment for stage III colorectal cancer); Herceptin as a preventive treatment for the return of breast cancer in some women; Hepsera (for hepatitis B ... - Jerusalem Post

Valeant Pharmaceuticals Reports Positive Data from Pradefovir ...  Mar 16, 2006
...were45 percent, 63 percent, 56 percent, and 71 percent for the pradefovir5 mg, 10 mg, 20 mg, and 30 mg groups, respectively, and 36 percent forthe Hepsera group ... - Finanzen.net

Metabasis Therapeutics Reports on Financial Results and Business ...  Mar 23, 2006
...in the 30 mg (QD) pradefovir cohort achieving undetectable HBV DNA (<400 c/mL) was almost double that of patients receiving 10 mg (QD) of Hepsera (71% versus 36 ... - PR Newswire

Baraclude Trumps Epivir as HBV Therapy  Mar 8, 2006
..."Either adefovir [Hepsera] or entecavir [Baraclude] is an appropriate first-line agent. Treatment probably should be continued indefinitely.". ... - MedPage Today



Gilead Sciences Welcomes Guidance From Nice On Treatment Of ...  Feb 22, 2006
...announced that the National Institute for Health and Clinical Excellence (NICE) has endorsed the use of its oral antiviral drug Hepsera® (adefovir dipivoxil ... - Medical News Today,

Gilead Sciences Announces Fourth Quarter and Full Year 2005 ...  Jan 30, 2006
...its US launch in August of 2004, as well as continued strong product sales for AmBisome(R) (amphotericin B) liposome for injection and Hepsera(R) (adefovir ... - Genetic Engineering News

Novartis/Idenix: entering hepatitis B market  Feb 7, 2006
...opportunity awaits telbivudine as none of the three antiviral therapies already available, namely GlaxoSmithKline's Zeffix, Gilead's Hepsera (adefovir dipivoxil ... - Pharmaceutical Business Review

Truvada Boosts Gilead's Revenue  Jan 30, 2006
...from a year ago, while product sales climbed for the ninth straight quarter as a result of the HIV drug Truvada and growth for the hepatitis B treatment Hepsera ... - TheStreet.com

Gilead 4th-qtr profit doubles but stock falls  Jan 30, 2006
Fourth-quarter sales of antifungal drug Ambisome rose 1 percent to $55.6 million and sales of hepatitis B drug Hepsera rose 43 percent to $51.2 million. ... - Reuters

GILEAD SCIENCES INC  Jan 11, 2006
Sales of Hepsera, GILD's treatment for hepatitis B, rose 58% on the year, to name another product. Most of GILD revenue stems from HIV treatment products. ... - Reuters

Tenofovir works as well for HBV in coinfected with 3TC resistance ...  Jan 27, 2006
Currently, two other oral anti-HBV drugs are approved in the United States - adefovir (Hepsera) and entecavir (Baraclude) - although only adefovir currently ... - Aidsmap

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional